Omeprazole contributed to seizure death, finds Somerset coroner
In News
Follow this topic
Bookmark
Record learning outcomes
Prescribed proton pump inhibitors (PPIs) contributed to a man’s death from post-haemorrhagic epilepsy, an inquest has found.
Peter Leech died at Musgrove Park Hospital on January 11 this year four days after he had a seizure “which was likely contributed to by an electrolyte disturbance secondary to proton pump inhibitor medication and a recent history of diarrhoea,” wrote Somerset area coroner Vanessa McKinlay in a report to prevent future deaths.
The inquest found that Mr Leech “died from the respiratory complication of post-haemorrhagic epilepsy to which proton pump inhibitor medication made a contribution”.
He had a history of seizures requiring hospitalisation following surgery in 2024 to remove a brain tumour which was complicated by a bleed on his brain.
The inquest found that PPIs have a “rare but recognised side effect of causing electrolyte disturbance” and can thereby lower the “threshold of risk of epileptic seizures”.
Mr Leech was started on omeprazole during a hospital admission with “no guidance” given to the GP on the duration of prescription, meaning it was prescribed on an ongoing basis.
The GP told the inquest he was unaware of the increased risk of seizure PPIs may lead to.
The report was issued to Somerset NHS Foundation Trust and Taunton Road Medical Centre.
The hospital trust refuted the coroner’s findings, with the chief executive stating: “While we recognise the rare association between prolonged PPI use and electrolyte disturbance, our professional assessment is that the evidence in this case does not demonstrate that the PPI directly caused, or materially increased the risk of, Mr Leech’s seizures.
“The medication was prescribed for an appropriate gastroprotective indication, and the documented seizure episodes occurred within the wider context of established epilepsy, structural brain injury and acute medical illness.
“We respectfully therefore do not agree with the report’s central clinical conclusion. We do, however, recognise the importance of ensuring that the indication, intended duration and monitoring requirements for medication initiated in secondary care are explicitly communicated to primary care.
“This represents a valid area for improvement, and the Trust will use the learning from this case to strengthen the clarity and consistency of its prescribing and discharge documentation.”